Key patent rights on phage display
Affitech has obtained worldwide patent protection on the use of phagemid display of antibodies and antibody fragments. In addition to its parental US patent, two further US divisional applications were approved in 2000, and in March of 2001 one of its European patents was granted. In addition, since Norway is not covered by other related patents, Affitech’s business strategy allows the company to practice all aspects of phage display-based antibody selection and to export non-infringing products for the international market.
rProtein L
A dominant patent position on rProtein L, an affinity protein for antibody fragment purification.
|
